Scopus BioPharma (Nasdaq: SCPS)

Transformational Immuno-Oncology Gene Therapy for Cancer Treatment

[Scopus BioPharma (Nasdaq: SCPS) @ScopusSCPS]

$SCPS: “Our new data demonstrate potent anti-tumor activity in malignant glioma. We are extremely excited about the significant potential of DUET-102 to be a game-changing and much-needed new treatment option for glioma patients.”

- Duet CEO Alan Horsager

[Scopus BioPharma (Nasdaq: SCPS) @ScopusSCPS]

$SCPS: Scopus BioPharma Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer.

See the @sitcancer announcement:

https://t.co/Y3sL53nQXL

[Scopus BioPharma (Nasdaq: SCPS) @ScopusSCPS]

$SCPS: “These new data suggest there is compelling potential for significant anti-tumor activity in gliomas utilizing a combination of DUET-102 with PD-1 inhibitors, such as Keytruda (Merck), Opdivo (Bristol-Myers Squibb) and Libtayo (Regeneron).���

- Dr. Kortylewski, Duet

[Scopus BioPharma (Nasdaq: SCPS) @ScopusSCPS]

$SCPS: Scopus BioPharma Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer on November 4th.

More information on the presentation at @SITCancer:

https://t.co/5rcjo5x4Io

[Scopus BioPharma (Nasdaq: SCPS) @ScopusSCPS]

Scopus BioPharma (Nasdaq: $SCPS) Subsidiary— Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer. For details on this SITC $SCPS presentation, see here:

https://t.co/cn8x0FvKxP

[Scopus BioPharma (Nasdaq: SCPS) @ScopusSCPS]

Learn more about the $SCPS recapitalization and its potential enhancements to shareholder value:

https://t.co/t1vXCOVOYR

[Scopus BioPharma (Nasdaq: SCPS) @ScopusSCPS]

Scopus BioPharma (Nasdaq: $SCPS) Completes Recapitalization Designed to Enhance Shareholder Value - Learn More About These $SCPS Transactions:

https://t.co/t1vXCOVOYR

[Scopus BioPharma (Nasdaq: SCPS) @ScopusSCPS]

Duet being positioned to go public in 2023.

[Scopus BioPharma (Nasdaq: SCPS) @ScopusSCPS]

Learn more about this exciting $SCPS appointment:

https://t.co/YHfKsfUKAd

[Scopus BioPharma (Nasdaq: SCPS) @ScopusSCPS]

Scopus BioPharma (Nasdaq: $SCPS) Announces Biotechnology Industry Leader Rejoins Board of Directors - Rafi Hofstein, Ph.D. Brings Invaluable Experience to $SCPS Board.

Learn More:

https://t.co/YHfKsfUKAd

[Scopus BioPharma (Nasdaq: SCPS) @ScopusSCPS]

“I am delighted to resume serving on the $SCPS Board. Having founded and nurtured many successful biotech companies, I am extremely excited about the Duet Platform, which encompasses an exceptional and comprehensive portfolio of immuno-oncology assets.” - Dr. Hofstein commented

[Scopus BioPharma (Nasdaq: SCPS) @ScopusSCPS]

@DuetThera See here for more information and to register for the conference:

https://t.co/9hnixAZBM1

[Scopus BioPharma (Nasdaq: SCPS) @ScopusSCPS]

$SCPS is set to present at the LD Micro Main Event. See here for more details on this presentation:

https://t.co/9hnixAZBM1

[Scopus BioPharma (Nasdaq: SCPS) @ScopusSCPS]

@DuetThera The $SCPS in-person presentation will be part of Track 4 on Tuesday, October 12, 2021 at 11 AM ET / 8 AM PT at the Luxe Sunset Bel-Air in Los Angeles. The presentation will also be available for viewing on-demand on the LD Micro conference website.